In this study, we demonstrated that PI4KA is involved in intrinsic chemoresistance of leukemia and leads to poor response to chemotherapeutic drugs and developed a PI4KA-targeting strategy to sensitize leukemia to adjuvant chemotherapy in proof-of-concept preclinical testing. The gene discussed is PI4KA; the disease is leukemia.